Logo image of MAK.DE

MATERNUS-KLINIKEN AG (MAK.DE) Stock Fundamental Analysis

FRA:MAK - DE0006044001 - Common Stock

1.16 EUR
+0.03 (+2.65%)
Last: 9/2/2025, 7:00:00 PM
Fundamental Rating

1

Overall MAK gets a fundamental rating of 1 out of 10. We evaluated MAK against 28 industry peers in the Health Care Providers & Services industry. MAK has a bad profitability rating. Also its financial health evaluation is rather negative. MAK is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

MAK had negative earnings in the past year.
In the past year MAK had a positive cash flow from operations.
MAK had negative earnings in each of the past 5 years.
MAK had a positive operating cash flow in each of the past 5 years.
MAK.DE Yearly Net Income VS EBIT VS OCF VS FCFMAK.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M

1.2 Ratios

Looking at the Return On Assets, with a value of -9.47%, MAK is doing worse than 92.86% of the companies in the same industry.
Industry RankSector Rank
ROA -9.47%
ROE N/A
ROIC N/A
ROA(3y)-6.64%
ROA(5y)-6.3%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MAK.DE Yearly ROA, ROE, ROICMAK.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 40 -40 60 -60

1.3 Margins

Looking at the Gross Margin, with a value of 85.47%, MAK belongs to the top of the industry, outperforming 82.14% of the companies in the same industry.
In the last couple of years the Gross Margin of MAK has remained more or less at the same level.
MAK does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 85.47%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0%
GM growth 5Y0.65%
MAK.DE Yearly Profit, Operating, Gross MarginsMAK.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 40 60 80

More info and screens

1

2. Health

2.1 Basic Checks

MAK does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MAK has about the same amount of shares outstanding.
The number of shares outstanding for MAK remains at a similar level compared to 5 years ago.
The debt/assets ratio for MAK has been reduced compared to a year ago.
MAK.DE Yearly Shares OutstandingMAK.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M
MAK.DE Yearly Total Debt VS Total AssetsMAK.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

MAK has an Altman-Z score of -0.83. This is a bad value and indicates that MAK is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -0.83, MAK is not doing good in the industry: 82.14% of the companies in the same industry are doing better.
The Debt to FCF ratio of MAK is 14.20, which is on the high side as it means it would take MAK, 14.20 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of MAK (14.20) is worse than 67.86% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 14.2
Altman-Z -0.83
ROIC/WACCN/A
WACC5.12%
MAK.DE Yearly LT Debt VS Equity VS FCFMAK.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M

2.3 Liquidity

MAK has a Current Ratio of 0.29. This is a bad value and indicates that MAK is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of MAK (0.29) is worse than 89.29% of its industry peers.
MAK has a Quick Ratio of 0.29. This is a bad value and indicates that MAK is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.28, MAK is not doing good in the industry: 89.29% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.29
Quick Ratio 0.28
MAK.DE Yearly Current Assets VS Current LiabilitesMAK.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

More info and screens

0

3. Growth

3.1 Past

MAK shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -1.28%.
Looking at the last year, MAK shows a decrease in Revenue. The Revenue has decreased by -4.12% in the last year.
MAK shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -3.82% yearly.
EPS 1Y (TTM)-1.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.75%
Revenue 1Y (TTM)-4.12%
Revenue growth 3Y-3.63%
Revenue growth 5Y-3.82%
Sales Q2Q%124.88%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MAK.DE Yearly Revenue VS EstimatesMAK.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
MAK.DE Yearly EPS VS EstimatesMAK.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 -0.02 -0.04 -0.06

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

MAK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MAK.DE Price Earnings VS Forward Price EarningsMAK.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

MAK's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. MAK is more expensive than 78.57% of the companies in the same industry.
100.00% of the companies in the same industry are more expensive than MAK, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 1.85
EV/EBITDA 40.86
MAK.DE Per share dataMAK.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

MAK does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MATERNUS-KLINIKEN AG

FRA:MAK (9/2/2025, 7:00:00 PM)

1.16

+0.03 (+2.65%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)07-21 2025-07-21
Earnings (Next)09-30 2025-09-30
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners81.7%
Ins Owner ChangeN/A
Market Cap24.33M
Analysts45.71
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.24
P/FCF 1.85
P/OCF 1.3
P/B N/A
P/tB N/A
EV/EBITDA 40.86
EPS(TTM)-0.68
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.63
FCFY54%
OCF(TTM)0.89
OCFY76.68%
SpS4.88
BVpS-2.65
TBVpS-3.28
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -9.47%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 85.47%
FCFM 12.84%
ROA(3y)-6.64%
ROA(5y)-6.3%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0%
GM growth 5Y0.65%
F-Score3
Asset Turnover0.68
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 14.2
Debt/EBITDA 26.69
Cap/Depr 54.86%
Cap/Sales 5.39%
Interest Coverage N/A
Cash Conversion 391.6%
Profit Quality N/A
Current Ratio 0.29
Quick Ratio 0.28
Altman-Z -0.83
F-Score3
WACC5.12%
ROIC/WACCN/A
Cap/Depr(3y)25.39%
Cap/Depr(5y)18.15%
Cap/Sales(3y)2.49%
Cap/Sales(5y)1.78%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.75%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-4.12%
Revenue growth 3Y-3.63%
Revenue growth 5Y-3.82%
Sales Q2Q%124.88%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y43.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y55.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y77.47%
OCF growth 3Y-40.8%
OCF growth 5Y-16.54%